# Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer

> **NCT07663513** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 36 (estimated)

## Conditions studied

- Ovarian Cancers

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab Injection + Bevacizumab + Paclitaxel + Carboplatin

## Key facts

- **NCT ID:** NCT07663513
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663513, "Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07663513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*